デフォルト表紙
市場調査レポート
商品コード
1179872

糖尿病性神経障害性足潰瘍の世界市場-2023-2030

Global Diabetic Neurotherapy Foot Ulcers Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
糖尿病性神経障害性足潰瘍の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

糖尿病性神経障害性足潰瘍の市場規模は、予測期間(2023-2030年)においてCAGR8.4%で成長すると予測されています。

下肢の切断につながる足の傷で最も頻度が高いのは、糖尿病性潰瘍です。一般開業医は、糖尿病性足部疾患の早期発見や予防に極めて重要な役割を担っています。糖尿病足の管理には、主な切断の危険因子に関する深い知識、日常的な評価、そして細心の予防メンテナンスが必要です。最も頻繁に発生する潰瘍形成の危険因子には、末梢動脈閉塞性疾患、足の構造的変形、糖尿病性神経障害などがあります。

市場力学

糖尿病性神経治療足潰瘍市場を牽引する主な要因は、糖尿病性足潰瘍の数の増加によって拡大が加速していること、市場は治療技術の進歩によって牽引されること、そして特定の種類の足潰瘍に利用できる特定の包帯があることです。

糖尿病性足潰瘍の増加により拡大が加速しています。

糖尿病患者は糖尿病性足潰瘍を発症しやすく、足の切断を余儀なくされることもあります。また、インスリン治療を受けている糖尿病患者さんは、足潰瘍を発症しやすいと言われています。糖尿病だけでなく、肥満、腎臓、眼、心臓に問題がある方も糖尿病性足潰瘍を発症する可能性があります。タバコやアルコールの使用は、いずれも病気のリスクを高めると言われています。

米国国立衛生研究所によると、全世界で年間910万~2610万個の糖尿病性足潰瘍が発生していると言われています。一生のうち、糖尿病患者の15~25%が糖尿病性足潰瘍にかかると言われています。糖尿病と診断される人が年々増えているため、糖尿病性足潰瘍の有病率は必然的に高くなると考えられます。糖尿病性足潰瘍はどの年齢でも発症しますが、45歳以上の糖尿病患者に最も多くみられます。足潰瘍を持つアメリカ人の大半は、ラテン系アメリカ人、アフリカ系アメリカ人、ネイティブ・アメリカンです。したがって、糖尿病性足潰瘍の発生率の増加によって成長が加速されるのです。

コストのかかる高度な創傷ケア製品や糖尿病性神経障害性足潰瘍(DME)の治療が、市場の成長を妨げると予想されます。

糖尿病性足潰瘍は、糖尿病の最も一般的な症状であり、死亡の主な原因でもあります。細胞外タンパク質、治療薬、その他の選択肢が高価になりすぎたため、代替治療法の技術開発が進んでいることが、市場の成長を鈍化させると予想されます。

COVID-19の影響分析

2019年12月のCOVID-19ウイルス発生以降、ウイルスは75カ国以上に拡大し、世界保健機関は公衆衛生上の緊急事態を宣言しました。例えば、世界保健機関の調査によると、2021年7月時点で、コロナウイルス(COVID-19)の顕在化により、世界で約1億9000万人が感染しています。

COVID-19が経済に影響を与える主な方法は、需給を直接的に変化させること、流通網を混乱させること、企業や金融市場に経済的影響を与えることの3つです。中国、インド、サウジアラビア、アラブ首長国連邦、エジプトなど多くの国では、広範囲に及ぶ封鎖により、ある場所から別の場所へ医薬品を移動することが困難になっています。さらに、COVID-19のパンデミックは、世界の糖尿病性足潰瘍治療市場の業界参入企業にとって、さまざまな面で大きな障害となっています。医薬品製剤の製造に必要な原材料の入手は、輸送の不規則性によって引き起こされる大きな問題の1つです。また、COVID-19やその他の生命を脅かす病気の患者が増加しているため、流通業者は店舗からの製品需要が不規則であることを確認しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 糖尿病性足潰瘍の増加により拡大が加速
      • 治療技術の進歩が市場を牽引
    • 抑制要因
      • 高価な先進創傷治療製品および治療法が市場拡大を抑制
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 潰瘍タイプ別

  • 神経障害性潰瘍
  • 虚血性潰瘍
  • 神経虚血性潰瘍

第8章 治療法別

  • 創傷被覆保護材
  • 生物学的製剤
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • ロングタームケアセンター
  • 外来手術センター
  • 在宅医療

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • Medtronic
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Organogenesis, Inc
  • Acelity L.P., Inc
  • B Braun Melsungen AG
  • Coloplast Corp
  • Medline Industries, Inc
  • 3M Healthcare
  • Molnlycke Health Care AB
  • Hyper oil
  • Smith & Nephew Plc.

第13章 糖尿病性神経障害性足潰瘍の世界市場-DataM

目次
Product Code: DMPH28

Market Overview

Diabetic Neuropathic Foot Ulcers Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 8.4% during the forecast period (2023-2030).

The most frequent foot wounds resulting in lower extremity amputation are diabetic ulcers. General practitioners are crucial in the early detection or prevention of diabetic foot problems. The management of the diabetic foot necessitates in-depth familiarity with the primary amputation risk factors, routine evaluation, and meticulous preventive maintenance. The most frequent ulcer-forming risk factors include peripheral artery occlusive disease, structural foot deformity, and diabetic neuropathy.

Market Dynamics

The major factors driving the global diabetic neurotherapy foot ulcers market are the expansion is accelerated by the increasing number of diabetic foot ulcers, the market will be driven by treatment technology advancement and there are specific dressings available for a particular type of foot ulcer.

The expansion is accelerated by the increasing number of diabetic foot ulcers.

Patients with diabetes are prone to developing diabetic foot ulcers, which can necessitate the amputation of the leg. Patients with diabetes who use insulin to control their condition are more likely to develop a foot ulcer. In addition to diabetes, individuals with obesity, kidney, eye, and heart issues may also develop diabetic foot ulcers. Use of tobacco and alcohol both raises the risk of the illness.

According to the National Institutes of Health (U.S.A.), between 9.1 and 26.1 million diabetic foot ulcers occur annually over the world. In their lifetime, 15 to 25% of people with diabetes mellitus will get a diabetic foot ulcer. The prevalence of diabetic foot ulcers will inevitably rise as more people are diagnosed with diabetes each year. Although diabetic foot ulcers can develop at any age, they are most common in those with diabetes mellitus who are over 45. The majority of Americans with foot ulcers are Latinos, African Americans, and Native Americans. Thus, the growth is sped up by an increase in the incidence of diabetic foot ulcers.

Costly advanced wound care products and therapies of diabetic neurotherapy foot ulcers (DME) is expected to hamper the market's growth.

A diabetic foot ulcer is the most prevalent consequence of diabetes and a substantial cause of death. It is anticipated that ongoing technical developments in therapeutic alternatives will slow the market's growth because extracellular proteins, therapeutic agents, and other options have become too expensive.

COVID-19 Impact Analysis

The virus has spread to over 75 countries since the COVID-19 viral outbreak in December 2019, and the World Health Organization declared it a public health emergency. For instance, as of July 2021, about 190 million people worldwide were infected due to the coronavirus (COVID-19) manifestation, according to a study from the World Health Organization.

Three main ways that COVID-19 can affect the economy are directly altering supply and demand, disrupting distribution networks, and having an economic impact on businesses and financial markets. Many nations, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, have difficulty moving pharmaceuticals from one location to another due to widespread lockdowns. Furthermore, the COVID-19 pandemic poses significant obstacles for industry participants in the worldwide diabetic foot ulcer therapy market on numerous fronts. The availability of raw materials required to make pharmaceutical formulations is one of the major problems caused by transportation irregularities. Additionally, because of a rise in patients with COVID-19 and other life-threatening illnesses, distributors see irregular demand for their products from stores.

Segment Analysis

The wound care dressing diabetic Neurotherapy foot ulcers-type segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The advanced wound dressings segment dominated the market for treating diabetic foot ulcers worldwide. There are many kinds of hydrogel dressings for wound treatment, including alginate dressings, hydro fiber dressings, surgical dressings, and others. Foam dressings are the most popular type of wound care treatment nowadays. Patients who have non-healing wounds can benefit from advanced wound care dressings. It is an active non-woven wound dressing made entirely of natural biopolymer. The 360-degree, dynamic mode of action of wound care dressings allows for efficient discharge control, pain reduction, infection control, active wound healing, and scar improvement. The excellent absorption capacity and painless removal of wound care dressings enhance patient comfort. As a result, they are widely employed for the care of wounds in various phases, and key players are also releasing new products, which boosts the market for this category.

For instance, in October 2022, A new line of wound dressings named Theruptor Novo was introduced by Bengaluru-based Healthium Medtech for treating chronic wounds, including leg and foot ulcers caused by diabetes. With the introduction of Theruptor Novo, Healthium expands the range of proprietary solutions it already offers in the market for advanced wound dressings.

For instance, in September 2021, The American Company Human Biosciences (HBS) hinted that it would soon launch two wound care products in the Indian market. The two items have the names "Medifil" and "Skin Temp, according to an announcement from the company. The company plans to offer two of its wound care management products, "Medifil" and "Skin Temp" in India soon.

Geographical Analysis

North America holds the largest market share in the global diabetic neurotherapy foot ulcers market.

The most prevalent illness in this age range is diabetes, which frequently results in diabetic foot ulcers. The prevalence of diabetic foot ulcers has increased due to people living more sedentary lifestyles. In this region, diabetes affects one in two people, which has helped to increase the demand for diabetic foot ulcer treatments. The International Diabetes Federation 2021 estimates that 51 million people in North America and the Caribbean now have diabetes. More than 20 million Americans are thought to experience peripheral neuropathy. However, given that not everyone who displays neuropathy symptoms is tested for the condition and that tests are currently not developed to detect all forms of neuropathy, this number may be much higher.

Major market competitors, rising healthcare GDP spending, and enhanced reimbursement for DFU therapy primarily influence the region's market growth. According to the Canadian Diabetes Association 2020, diabetes accounts for 70% of lower limb amputations carried out in hospitals and are the most common reason for non-traumatic lower limb amputation in Canadian adults. Canadian individuals with diabetes are nearly 20 times more likely than the general population to have non-traumatic lower limb amputations, 85% of which are preceded by a foot ulcer.

Competitive Landscape

The diabetic neurotherapy foot ulcers market is moderately competitive with local and global companies' presence Medtronic, Organogenesis, Inc, Acelity L.P., Inc, B Braun Melsungen AG, Coloplast Corp, Smith & Nephew Plc, Medline Industries, Inc, 3M Healthcare, Molnlycke Health Care AB, Hyper oil and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in June 2022, Smith + Nephew will spend over $100 million to build a top-notch research and development, manufacturing, and flexible office building. A funding from the UK government will also help to fund the development. In its first ten years of operation, the new factory is anticipated to support sales of more than $10 billion.

Hyper Oil.

Overview: The product's patent license was obtained by RI.MOS in 2005, and clinical trials for the treatment of ulcers and bedsores in humans commenced in 2006. Even the most hopeful predictions were surpassed by the initial results of the Clinica Barbantini of Lucca, Tuscany, one of the most significant National reference centers, conducted by the Department of Vulnology. Holoil (a brand for the Italian market) and Hyperoil (a brand for international markets) received CE approval as Class IIb Medical Devices in 2008. In 2009, RI.MOS launched the Hypermix for Veterinary Use and Holoil for Human Use brands to promote the product in the Italian market (in 2011).

Product Portfolio:

Fast Healing Advanced Wound Dressing: Infection prevention, re-epithelialization support, fibrinolytic action, and other benefits are provided by hyperoil. At all stages of tissue repair, it only needs the assistance of secondary dressings to protect and/or absorb, as necessary, while carrying out all other essential tasks on its own.

The global diabetic neurotherapy foot ulcers market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The expansion is accelerated by the increasing number of diabetic foot ulcers
      • 4.1.1.2. The market will be driven by treatment technology advancement
    • 4.1.2. Restraints:
      • 4.1.2.1. Costly advanced wound care products and therapies restrain market expansion
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ulcer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 7.1.2. Market Attractiveness Index, By Ulcer Type
  • 7.2. Neuropathic Ulcers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Ischemic Ulcers
  • 7.4. Neuro-Ischemic Ulcers

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Wound Care Dressings
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics
  • 8.4. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Long term Care Centres
  • 9.5. Ambulatory Surgical Centres
  • 9.6. Home Care setting

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Medtronic
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Organogenesis, Inc
  • 12.3. Acelity L.P., Inc
  • 12.4. B Braun Melsungen AG
  • 12.5. Coloplast Corp
  • 12.6. Medline Industries, Inc
  • 12.7. 3M Healthcare
  • 12.8. Molnlycke Health Care AB
  • 12.9. Hyper oil
  • 12.10. Smith & Nephew Plc.

LIST NOT EXHAUSTIVE

13. Global Diabetic Neurotherapy Foot Ulcers Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us